Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial

scientific article published on 14 May 2018

Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JTOS.2018.05.001
P698PubMed publication ID29772277

P50authorMargarita CalongeQ43119624
Amalia Enríquez-de-SalamancaQ55704458
María Jesús González-GarcíaQ55704459
Itziar FernándezQ56440402
Alberto López-MiguelQ57032993
Virginia L CalderQ61653903
Carmen García-VázquezQ79983690
José Pinto-FragaQ86594548
Alberto López-de-la-RosaQ86594554
P2093author name stringMichael E Stern
P433issue3
P921main subjectbiomarkerQ864574
eye diseaseQ3041498
phase III clinical trialQ42824827
P304page(s)368-376
P577publication date2018-05-14
P1433published inThe Ocular SurfaceQ15764153
P1476titleSeverity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial
P478volume16

Reverse relations

cites work (P2860)
Q64244837Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye
Q99551257In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay
Q61811294Review of Biomarkers in Ocular Matrices: Challenges and Opportunities

Search more.